CRISPR Therapeutics(US:CRSP)2025-11-10 13:10Financial Performance - Net loss for Q3 2025 was $106.4 million, compared to a net loss of $85.9 million in Q3 2024[14]. - Total revenue for Q3 2025 was $889,000, compared to $602,000 in Q3 2024, representing a 47.7% increase year-over-year[30]. - The company reported a comprehensive loss of $105,496,000 for Q3 2025, compared to a comprehensive loss of $72,498,000 in Q3 2024[30]. - Cash and cash equivalents as of September 30, 2025, were $286,497,000, a decrease from $298,257,000 as of December 31, 2024[32]. - The basic weighted-average common shares outstanding increased to 91,305,337 in Q3 2025 from 85,234,926 in Q3 2024[30]. Research and Development - R&D expenses decreased to $58.9 million in Q3 2025 from $82.2 million in Q3 2024, driven by lower external research costs[12]. - Research and development expenses for Q3 2025 were $58,902,000, down from $82,160,000 in Q3 2024, a decrease of 28.4%[30]. - CTX460™, targeting AATD, demonstrated over 90% mRNA correction in preclinical data, with clinical trial initiation planned for mid-2026[2][8]. - CRISPR Therapeutics is advancing its in vivo gene editing pipeline, including CTX310 and CTX320, targeting significant unmet needs in cardiovascular and metabolic diseases[2][8]. - CRISPR Therapeutics has established a proprietary lipid nanoparticle delivery platform to enable gene editing in the liver, enhancing its gene editing capabilities[18]. Product Development and Collaborations - Positive Phase 1 data for CTX310® presented at the AHA Scientific Sessions, highlighting its potential to lower triglycerides and LDL after a single IV administration[2]. - CASGEVY® has seen nearly 300 patient referrals to Authorized Treatment Centers, with approximately 165 patients completing their first cell collection and 39 receiving infusions; over $100 million in total revenue expected for 2025[2][4]. - Pediatric development of exa-cel is advancing, with enrollment in two global Phase 3 studies completed; initial data to be presented at the ASH annual meeting[2][3]. - First patient dosed in the Phase 2 trial of SRSD107 for thromboembolic disorders, with expansion to additional sites in Europe[12]. - The collaboration with Sirius Therapeutics focuses on developing SRSD107, a long-acting siRNA targeting Factor XI, with shared costs and profits[20][21]. Financial Position - Strong balance sheet with approximately $1.9 billion in cash, cash equivalents, and marketable securities as of September 30, 2025[2][13]. - The company has a total of $1,629,213,000 in marketable securities as of September 30, 2025, compared to $1,605,569,000 at the end of 2024[32]. - Collaboration expense increased to $57.1 million in Q3 2025, primarily due to timing of cost deferral limits reached in 2024[12][14].